FDA Inspection 1122265 — Biotest Pharmaceuticals Corporation
The FDA completed an inspection of Biotest Pharmaceuticals Corporation on February 7, 2020 in Brookings, SD. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 7, 2020
- Fiscal Year
- 2020
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Brookings, SD (United States)